Major molecular response during the first year of dasatinib, imatinib or nilotinib treatment for newly diagnosed chronic myeloid leukemia: a network meta-analysis.

@article{Signorovitch2014MajorMR,
  title={Major molecular response during the first year of dasatinib, imatinib or nilotinib treatment for newly diagnosed chronic myeloid leukemia: a network meta-analysis.},
  author={James Edward Signorovitch and Rajeev Ayyagari and William Michael Reichmann and Eric Qiong Wu and Lei Chen},
  journal={Cancer treatment reviews},
  year={2014},
  volume={40 2},
  pages={
          285-92
        }
}
OBJECTIVE No randomized trials have directly compared dasatinib with nilotinib for the treatment of newly diagnosed chronic myeloid leukemia in the chronic phase. The objective of this study was to indirectly compare these therapies using evidence from randomized trials versus imatinib, the current standard of care. METHODS Randomized trials that included either dasatinib or nilotinib as first-line treatment for chronic myeloid leukemia were identified in a systematic review. Inclusion and… CONTINUE READING
BETA
Tweets
This paper has been referenced on Twitter 2 times. VIEW TWEETS

From This Paper

Topics from this paper.

Similar Papers

Loading similar papers…